Animal Models of Cognitive Impairment Frontiers in Neuroscience
Edward D. Levin
Animal Models of Cognitive Impairment Frontiers in Neuroscience - illustrated - London CRC Press 2006 - 400 pages
Contents:
1 Introduction
2 Muscarinic Receptor Antagonists in Rats
3 Nicotinic Receptor Antagonists in Rats
4 Involvement of the NMDA System in Learning and Memory
5 Animal Models and the Cognitive Effects of Ethanol
6 Animal Models of Cognitive Impairment Produced by Developmental Lead Exposure
Consequences Conditioning and Cortex
What Animal Models Have Told Us
9 Modeling Cognitive Deficits Associated with Parkinsonism in the ChronicLowDose MPTPTreated Monkey
10 Cognitive Impairment in Transgenic Mouse Models of Amyloid Deposition
11 Cholinergic Receptor Knockout Mice
12 Assessments of Cognitive Deficits in Mutant Mice
13 Cognitive Pharmacology in Aging Macaques
14 Cognitive Impairment following Traumatic Brain Injury
15 Cognitive Impairment Models Using Complementary Species
16 Cognition Models and Drug Discovery
Index
The costs associated with a drug's clinical trials are so significant that it has become necessary to validate both its safety and efficacy in animal models prior to the continued study of the drug in humans.
Featuring contributions from distinguished researchers in the field of cognitive therapy research, Animal Models of Cognitive Impairmen
1420004336 9781420004335 = acetylcholine acquisition agonist Alzheimer’s disease amygdala amyloid animal models antagonist Aroclor assessed attention Behav behavior brain injury Brain Res choice cholinergic cognitive cognitive deficits cognitive function cognitive impairment cortex cortical cues delay developmental discrimination reversal disruption dopamine dose drug dysfunction effects of ethanol ethanol exposed fear conditioning foot shock gene genetic gestation goldfish hippocampus human increased inhibition interval knockout latency lead exposure learning and memory lesions lever pressing Levin M1 mAChR mAChR KO mice mecamylamine MeHg memory deficits memory impairment methylmercury mg/kg monkeys Morris water maze motor mouse MPTP muscarinic mutant nAChR neural neurons Neurosci Neurotoxicol nicotinic nicotinic acetylcholine receptor NMDA receptor nonspatial observed PCB exposure performance Pharmacol pharmacological phenotype potential processes Psychopharmacology radial arm maze rats reinforcement response retention rodents role schedule schizophrenia scopolamine sensitivity session spatial learning stimulus studies task Teratol Toxicol transgenic transgenic mice trials visual zebrafish
-- Science › Life Sciences › General -- Medical / Neurology --Science / Life Sciences / General --Technology & Engineering / Agriculture / General --Science / Life Sciences / Neuroscience
616.8 LEV
Animal Models of Cognitive Impairment Frontiers in Neuroscience - illustrated - London CRC Press 2006 - 400 pages
Contents:
1 Introduction
2 Muscarinic Receptor Antagonists in Rats
3 Nicotinic Receptor Antagonists in Rats
4 Involvement of the NMDA System in Learning and Memory
5 Animal Models and the Cognitive Effects of Ethanol
6 Animal Models of Cognitive Impairment Produced by Developmental Lead Exposure
Consequences Conditioning and Cortex
What Animal Models Have Told Us
9 Modeling Cognitive Deficits Associated with Parkinsonism in the ChronicLowDose MPTPTreated Monkey
10 Cognitive Impairment in Transgenic Mouse Models of Amyloid Deposition
11 Cholinergic Receptor Knockout Mice
12 Assessments of Cognitive Deficits in Mutant Mice
13 Cognitive Pharmacology in Aging Macaques
14 Cognitive Impairment following Traumatic Brain Injury
15 Cognitive Impairment Models Using Complementary Species
16 Cognition Models and Drug Discovery
Index
The costs associated with a drug's clinical trials are so significant that it has become necessary to validate both its safety and efficacy in animal models prior to the continued study of the drug in humans.
Featuring contributions from distinguished researchers in the field of cognitive therapy research, Animal Models of Cognitive Impairmen
1420004336 9781420004335 = acetylcholine acquisition agonist Alzheimer’s disease amygdala amyloid animal models antagonist Aroclor assessed attention Behav behavior brain injury Brain Res choice cholinergic cognitive cognitive deficits cognitive function cognitive impairment cortex cortical cues delay developmental discrimination reversal disruption dopamine dose drug dysfunction effects of ethanol ethanol exposed fear conditioning foot shock gene genetic gestation goldfish hippocampus human increased inhibition interval knockout latency lead exposure learning and memory lesions lever pressing Levin M1 mAChR mAChR KO mice mecamylamine MeHg memory deficits memory impairment methylmercury mg/kg monkeys Morris water maze motor mouse MPTP muscarinic mutant nAChR neural neurons Neurosci Neurotoxicol nicotinic nicotinic acetylcholine receptor NMDA receptor nonspatial observed PCB exposure performance Pharmacol pharmacological phenotype potential processes Psychopharmacology radial arm maze rats reinforcement response retention rodents role schedule schizophrenia scopolamine sensitivity session spatial learning stimulus studies task Teratol Toxicol transgenic transgenic mice trials visual zebrafish
-- Science › Life Sciences › General -- Medical / Neurology --Science / Life Sciences / General --Technology & Engineering / Agriculture / General --Science / Life Sciences / Neuroscience
616.8 LEV